Bristol-Myers Squibb CoBSP:BMYB34 +2.49%71 OCF Margin % is 9.61% as of Mar. 2026, which is 69% below its 10-year median of 31.06. GuruFocus rates BSP:BMYB34 with a GF Score™ of 71/100 and a GF Value™ of R$274.39 (Fairly Valued). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 90.09% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BMYB34 vs PFE, GILD, AMGN: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (BSP:BMYB34) has a OCF Margin % of 9.61% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bristol-Myers Squibb Co and its competitors. This is 69% below median its historical median of 31.06. Over the past decade, Bristol-Myers Squibb Co's OCF Margin % has ranged from 15.74 to 34.94. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #95 out of 959 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Bristol-Myers Squibb Co's OCF Margin % too high?
Bristol-Myers Squibb Co's current OCF Margin % of 9.61% is 69% below median its 10-year median of 31.06. Over the past 10 years, this metric has ranged from a low of 15.74 to a high of 34.94. The Drug Manufacturers industry median OCF Margin % is 9.95. Bristol-Myers Squibb Co's value of 9.61% is 3.4% below this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #95 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's OCF Margin % compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #95 out of 959 companies for OCF Margin %. This places Bristol-Myers Squibb Co in the top 10% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Bristol-Myers Squibb Co's value of 9.61% is 3.4% below this benchmark. Historically, Bristol-Myers Squibb Co's own OCF Margin % has ranged from 15.74 to 34.94 over the past decade. While the company's 10-year median is 31.06 vs. the industry median of 9.95, Bristol-Myers Squibb Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current OCF Margin % of 9.61% is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current OCF Margin % is 9.61%, which is 69% below median its own 10-year median of 31.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BSP:BMYB34) is currently considered Fairly Valued. The stock's GF Value™ is R$274.39, compared to a current price of R$287.84 — trading 4.9% above its estimated fair value. The current OCF Margin % is 9.61%, which is 69% below median its 10-year median of 31.06 and 3.4% below the Drug Manufacturers industry median of 9.95. Bristol-Myers Squibb Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BSP:BMYB34), the current OCF Margin % is 9.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (BSP:BMYB34) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of R$287.84 is trading 4.9% above its estimated GF Value™ of R$274.39.
GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.
Key valuation signals for BSP:BMYB34:
OCF Margin %: 9.61% (69% below median its 10-year median of 31.06)
GF Value™: R$274.39 vs. price of R$287.84 (4.9% above fair value)
Industry Position: 3.4% below the Drug Manufacturers median (#95 of 959)
No single metric tells the full story. See the BSP:BMYB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score
Get the complete analysis for BSP:BMYB34
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BMYB34 has been successfully added to your 
